Figure 1.
Probability plot of Sharp/van der Heijde score of the hands at the 5-year disease duration.
Each point on the plot represents the Sharp/van der Heijde score (SHS) of the hands at the 5-year disease duration, which representing approximate value of the radiographic progression in the first 5 years after onset of RA, in an individual patient. A zero value represents a patient without any radiographic progression, and the right-side tail represents patients with the most progression.
Figure 2.
Histogram of distribution of the log-transformed SHS (hands).
Table 1.
Demographic and clinical characteristics of patients at 5 years from onset.
Figure 3.
Boxplots representing the distribution of Sharp/van der Heijde score (SHS) of the hands in each category of independent risk factors for joint destruction.
Risk factors; the number of HLA-DRB1 shared epitope, the number of PADI4 risk alleles, ACPA status (negative [<4.5 IU/ml] and positive), gender (female and male) and age at onset (categorized as “age under 30”, “30 s”, “40 s”, “50 s”, “60 s” and “age over 70”). Each box represents the interquartile range of values, with the bold line showing the median value. The vertical lines show maximum and minimum value that fall within 1.5 box lengths, the open circles show extreme values >1.5 box plot lengths. The P values were given by the univariate linear regression analyses (a log-transformed SHS was used as the dependent variable). PADI4, peptidyl arginine deiminase type IV ACPA, anti-citrullinated peptide antibody.
Figure 4.
Boxplots representing the distribution of Sharp/van der Heijde score (SHS) of the hands according to the number of the risk factors.
Risk factors; SE allele carrier, PADI4 risk allele carrier, ACPA positive, female and age at onset under 50. Each box represents the interquartile range of values, with the bold line showing the median value. The vertical lines show maximum and minimum value that fall within 1.5 box lengths, the open circles show extreme values >1.5 box plot lengths. PADI4, peptidyl arginine deiminase type IV ACPA, anti-citrullinated peptide antibody.
Table 2.
Univariate linear regression analysis on putative risk factors for radiographic progression: non-genetic and genetic factors.
Table 3.
Stepwise multiple regression analysis on risk factors for radiographic progression (n = 830).